Survival in men older than 75 years with low- and intermediate-grade prostate cancer managed with watchful waiting with active surveillance
Methods: We performed survival analysis in a cohort of 18,599 men with low-risk tumors (early and localized tumors) who were 75 years or older at the time of prostate cancer diagnosis in the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database (from 1992 to 1998) and who were followed up through December 2003. WWAS was defined as having annual screening for prostate-specific antigen and/or digital rectal examination during the follow-up period. The risks of prostate cancer‐specific and all-cause death were compared by Cox regression models. The propensity score matching technique was used to address potential selection bias.
Results: In patients with well-differentiated (Gleason score 2‐4) and localized disease, those managed with WWAS without delayed treatment had higher risk of all-cause death (hazard ratio 1.20, 95% confidence interval 1.13‐1.28) but a substantially lower risk of prostate cancer‐specific death (hazard ratio 0.62, confidence interval 0.51‐0.75) than patients undergoing active treatment. Patients managed with WWAS with delayed treatment had comparable mortality outcomes. Sensitivity analyses based on propensity score matching yielded similar results.
Conclusion: In men older than 75 years with well-differentiated and localized prostate cancer, WWAS without delayed treatment had a lower risk of prostate cancer‐specific death and comparable all-cause death as compared with active treatment. Those patients in whom treatment was delayed had comparable mortality outcomes. Our results support WWAS as an initial management option for older men with well-differentiated and localized prostate cancer.
Document Type: Research Article
Publication date: 01 September 2015
Family Medicine and Community Health (FMCH) is an open-access journal focusing on subjects that are common and relevant to family medicine/general practice and community health. The journal publishes relevant content across disciplines such as epidemiology, public health, social and preventive medicine, research and evidence based medicine, community health service, patient education and health promotion and health ethics. The journal has a specific focus on the management of chronic illness particularly diabetes, ischaemic heart disease, chronic heart failure, hypertension, bronchial asthma, chronic obstructive airways disease and common mental illness. FMCH is published by Compuscript http://www.compuscript.com on behalf of the Chinese General Practice Press http://www.chinagp.net.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Membership Information
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites